HC Wainwright Reaffirms Buy Rating for Ovid Therapeutics (NASDAQ:OVID)

HC Wainwright reaffirmed their buy rating on shares of Ovid Therapeutics (NASDAQ:OVID – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $9.00 target price on the stock. Other analysts also recently issued reports about the stock. Wedbush began coverage on shares of Ovid Therapeutics […]

Related Keywords

United States ,China ,Jeremym Levin , ,Sg Americas Securities ,Jump Financial ,Ovid Therapeutics Company Profile ,Ovid Therapeutics Inc ,Citigroup ,Securities Exchange Commission ,China Universal Asset Management Co ,Wealth Management ,Ovid Therapeutics ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Universal Asset Management ,Therapeutics Inc ,Ovid Therapeutics Daily ,